Amy Lynn Werda

Title: Amy Lynn Werda: Innovator in Cancer Diagnostics

Introduction

Amy Lynn Werda is a prominent inventor based in North Brunswick, NJ (US). She has made significant contributions to the field of medical diagnostics, particularly in the area of cancer prediction and diagnosis. Her innovative work focuses on the PME-1 gene and its implications in endometrial cancer.

Latest Patents

Amy Lynn Werda holds 1 patent related to her research. The patent details methods for using PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer. It also discusses gene silencing of PME-1 to inhibit the epithelial to mesenchymal transition. The disclosed methods utilize siRNAs or shRNAs to target PME-1, effectively reducing its mRNA levels. This innovative approach aims to attenuate the epithelial to mesenchymal transition, thereby inhibiting the development of endometrial cancer. Additionally, a kit containing siRNA or shRNA reagents for attenuating PME-1 gene expression is included in her patent.

Career Highlights

Amy is currently associated with Medical Diagnostic Laboratories, LLC, where she continues her research and development efforts. Her work has the potential to significantly impact cancer diagnostics and treatment strategies.

Collaborations

Amy has collaborated with notable colleagues, including Lyndi Rice and Michelle Pusey, to advance her research initiatives.

Conclusion

Amy Lynn Werda's innovative contributions to cancer diagnostics through her research on PME-1 highlight her role as a leading inventor in the medical field. Her work not only enhances our understanding of endometrial cancer but also paves the way for future advancements in cancer treatment.